Antisense Therapeutics Limited (ATHJF)
Antisense Therapeutics Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Toorak, VIC, AU. The stock last traded at $0.01, down 76.00% on the session, giving a market capitalisation of $19.6M. Its beta of 0.87 implies it has historically moved less than the broad market.
Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory conditions, such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. The company's second candidate, ATL1103, is an advanced second-generation antisense medication. This drug works by blocking growth hormone receptor expression, which subsequently lowers levels of insulin-like growth factor-I (IGF-I) in the bloodstream, and has successfully completed Phase II clinical trials for diseases linked to excessive growth hormone activity. Antisense Therapeutics Limited was established in 2000 and operates from its base in Toorak, Australia.
Antisense Therapeutics Limited is most often compared with the following Healthcare names: